Stereotaxis Announces First European AF Procedures Performed With Magnetic Irrigated Catheter

November 5, 2007

ST. LOUIS, Nov. 5 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that the first atrial fibrillation procedures performed with its partnered magnetic irrigated catheter were successfully completed over the course of the past week. The magnetic irrigated catheter has CE Mark approval for the remote ablation of arrhythmias and is being released in phases to physicians in Europe. Details from completed cases will be provided at the Company's earnings call, which is scheduled for Thursday, November 8, 2007, at 8:30 a.m. Eastern Time.

"The first uses of our partnered irrigated catheter in Europe are a double achievement," said Bevil Hogg, CEO of Stereotaxis. "First, the cases were remarkable for their efficiency and efficacy, and we are extremely pleased with the results. Secondly, combined with our Stereotaxis Magnetic Navigation System and new NaviLine(TM) software, the irrigated catheter completes Stereotaxis' total solution for atrial fibrillation, a solution that we believe will significantly advance the treatment of complex arrhythmias and potentially become standard of care for a growing number of cases. Near term, we believe that widespread adoption of our partnered magnetic irrigated catheter in Europe will bring even greater simplicity and safety to atrial fibrillation procedures performed there, and we look forward to these clinical benefits becoming available to patients and clinicians in the U.S. after appropriate regulatory approval."

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada. Note that use of cardiac ablation catheters for treatment of atrial fibrillation is considered investigational in the United States.

About Forward Looking Statements

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE Stereotaxis
-0- 11/05/2007
/CONTACT: Jim Stolze, Chief Financial Officer, of Stereotaxis; or investors, Doug Sherk or Jenifer Kirtland, +1-415-896-6820, both for Stereotaxis; or Steve DiMattia, of EVC Group, Inc., +1-646-201-5445, for Stereotaxis/
/Web site: http://www.stereotaxis.com/
(STXS)

CO: Stereotaxis
ST: Missouri
IN: HEA MTC
SU: PDT

JN-KQ
-- AQM061 --
2613 11/05/2007 06:30 EDT http://www.prnewswire.com